Quick Answer
Edesa Biotech, Inc. reported Net Income Loss of -$7.19 million for the year ending 2025.
- Edesa Biotech, Inc. showed a decrease of -16.5% in Net Income Loss from 2024 to 2025.
- This data is from Edesa Biotech, Inc.'s annual report (Form 10-K), filed with the SEC on December 12, 2025.
- XBRL data for this metric is available from 2013 to 2025 (13 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2013: -$240.4 thousand | Q4 2013: -$5.58 million | Q1 2014: -$1.43 million | Q2 2014: $3.41 million | Q4 2014: -$1.34 million | Q1 2015: -$426.2 thousand | Q2 2015: $464.0 thousand | Q4 2015: -$1.63 million | Q1 2016: -$861.0 thousand | Q2 2016: -$1.19 million | Q4 2016: -$1.49 million | Q1 2017: -$1.10 million | Q2 2017: -$1.22 million | Q4 2017: -$1.40 million | Q1 2018: -$1.35 million | Q2 2018: -$411.8 thousand | Q4 2018: -$364.8 thousand | Q1 2019: -$528.8 thousand | Q2 2019: -$1.29 million | Q4 2019: -$1.09 million | Q1 2020: -$1.49 million | Q2 2020: -$1.77 million | Q4 2020: -$2.64 million | Q1 2021: -$2.26 million | Q2 2021: -$4.76 million | Q4 2021: -$4.38 million | Q1 2022: -$4.57 million | Q2 2022: -$5.79 million | Q4 2022: -$2.33 million | Q1 2023: -$2.33 million | Q2 2023: -$1.98 million | Q4 2023: -$1.68 million | Q1 2024: -$1.86 million | Q2 2024: -$1.67 million | Q4 2024: -$1.62 million | Q1 2025: -$1.59 million | Q2 2025: -$1.75 million | Q4 2025: -$2.25 million.
- Over the full 13 years of available data (2013 to 2025), Edesa Biotech, Inc.'s Net Income Loss has grown by 50.4%.
- Historical annual values: Fiscal year 2025: -$7.19 million | Fiscal year 2024: -$6.17 million | Fiscal year 2023: -$8.37 million | Fiscal year 2022: -$17.55 million | Fiscal year 2021: -$13.34 million | Fiscal year 2020: -$6.36 million | Fiscal year 2018: -$5.04 million | Fiscal year 2017: -$5.03 million | Fiscal year 2016: -$5.03 million | Fiscal year 2015: -$2.84 million | Fiscal year 2014: $1.13 million | Fiscal year 2014: -$8.44 million | Fiscal year 2013: -$14.50 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: